Expands Ocular Disease Treatment Pipeline
Unveiling INM-089 targeting AMD. InMed is expanding its rare cannabinoid cannabinol (CBN)-based ocular disease treatment pipeline with INM-089, targeting age-related macular degeneration (AMD). INM-089, a CBN analog, is InMed’s second ocular pharmaceutical program, with the company currently engaged in pre-clinical studies of INM-088, investigating its effects in the treatment of glaucoma. InMed’s ocular programs target leading causes of severe eyesight loss and blindness. Glaucoma is the second leading cause of blindness, affecting 78 million people worldwide. AMD is the most common cause of poor vision in older people. It is estimated that the disease affects one in eight people 50 years of age or older and is the most common cause of irreversible blindness in older people in developed countries. Some 200 million people worldwide have AMD, and according to some industry projections, that number is expected to rise to 300 million by 2040. While treatment options for glaucoma and AMD are available, none of them provides a curative or reversible solution to either disease. A novel approach to treating AMD. Just as in the case of INM-088 with respect to glaucoma, INM-089 offers a novel approach to the potential treatment of AMD, which causes damage to the retina at the back of the eye, resulting in severe vision deterioration. In this respect, a collaborative study between InMed and cannabinoid expert Dr. Mauro Maccarrone at the Università degli Studi dell’Aquila (Italy) identified a specific CBN analog (INM-089), among several that were screened, demonstrating that it improved retinal function in a pre-clinical in vivo AMD disease model. Although still years away from gaining any visibility on their ultimate success, following in the slip stream of the launch in October 2023 of InMed’s INM-901 program targeting Alzheimer’s disease, early studies indicate that INM-089 along with INM-088 can provide hope for the significant swaths of population affected by very hard to treat ocular diseases such as AMD and glaucoma.
Water Tower Research is built on the foundation of democratizing information flow. We bridge the growing information gap between companies and investors through our investor engagement strategies and open-access research platform.
Our research analysts are Wall Street veterans with the experience and knowledge to work with companies and investors in tandem. We provide access to the information and content that anchors the due diligence process for both professional money managers and individual investors. We leverage traditional research distribution channels and the best of modern digital strategies and tactics to amplify this information flow globally to engage all categories of investors and stakeholders.
Information flow is the foundation for creating investor awareness, knowledge, and engagement. Our mission is to help companies and investors have the tools they need and achieve their goals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.